Skip to content

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01262040
Enrollment
154
Registered
2010-12-17
Start date
2010-12-14
Completion date
2018-10-29
Last updated
2018-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer, Esophageal Carcinoma, Fallopian Tube Cancer, Gastrointestinal Carcinoma, Lung Cancer, Ovarian Cancer, Pancreatic Carcinoma, Peritoneal Cancer

Keywords

NBI, ENDOMETRIUM, FALLOPIAN TUBE, OVARY, PERITONEUM, Surgery, Lung, Pancreatic, Esophageal, thorascopic, laparoscopic, robotic, 10-180

Brief summary

The purpose of this study is to determine whether narrowband imaging (NBI) makes it easier for a surgeon to see cancer. NBI is a kind of light. Normally, white light is used during surgery. White light uses many wavelengths of light. NBI only uses two wavelengths which highlight the blood vessels. This makes it easier for the surgeon to see blood vessels. Tumors often have more blood vessels than normal tissue. As a result, NBI may make it easier for the surgeon to see small tumors. In this study the surgeon will look with both normal white light and NBI. This way a comparison can be made to determine which is superior. Improved identification of tumors allows doctors and patients to make informed decisions about whether treatment is needed after surgery. It also provides additional information to determine which treatments may be best.

Interventions

The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.

Sponsors

Memorial Sloan Kettering Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients must meet one (or more) of the following criteria: * Preoperative diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma (all stage, grade and histology) * Preoperative diagnosis of grade III endometrial carcinoma (all stage, all histology) * Preoperative diagnosis of uterine serous carcinoma (all stage, all grade) * Preoperative diagnosis of clear cell endometrial carcinoma (all stage, all grade) * Preoperative diagnosis of endometrial carcinosarcoma (all stage, all grade) * Gastrointestinal carcinoma (all histology, stage and grade) * Pancreatic carcinoma (all histology, stage and grade) * Lung cancer (all histology, stage and grade) * Esophageal carcinoma (all histology, stage and grade) * Suspected or pathologically confirmed metastatic disease to the lung (all disease primaries) * Suspected or pathologically confirmed malignant pleural effusion (all disease primaries) Patients must meet all of the following criteria: * Planned thorascopic robotic or laparoscopic surgical approach * \>18 years old * Not pregnant * Able to give consent Participation in other research protocols does not exclude a patient from participation in this study.

Exclusion criteria

* None

Design outcomes

Primary

MeasureTime frame
Determine the feasibility of Narrow Band Imaging (NBI) at the time of thorascopic, laparoscopic or robotic surgery.1 year

Secondary

MeasureTime frame
Determine what percentage of patients have surface metastasis identified with NBI that were not seen on white light imaging.1 year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026